HIV research has come a long way since the virus was discovered in the 1980s. Antiretroviral therapy was a major milestone that has changed the lives of millions; the…
Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a…
The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. …
Here are the top biotech companies in Oxford, a city with an old scientific tradition and an enormous output of biotech applications. Oxford is well known for its university, one…
UK biotech Immunocore has raised €116.7M in Series B funding to develop drugs that harness the body’s immune cells to fight cancer, viral infections, and autoimmune diseases. This latest funding…
Immunocore and the US biotech giant Genentech are building on their existing partnership to boost the clinical development of Immunocore's immunotherapy for treating solid tumors. In the agreement, Genentech, a…
Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on…
Still catching up on news? We've picked out the most exciting things that happened besides clinical results and finance. Here's the biggest biotech news of 2017. We've been recapping the…
The UK grants Immunocore access to a fast-track scheme that will make its immunotherapy IMCgp100 available to patients with uveal melanoma before approval. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA)…
This week marks the WHO's World Antibiotic Awareness Week. We had a look at some of the best work being done by biotechs to fight resistance. An estimated 154 million prescriptions for antibiotics…
Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but…
The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation…
This infographic gathers 10 of the best HIV treatments in Europe's pipeline that will help doctors worldwide fight against AIDS better than ever before. With an estimated 36.7 million people…
Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO 2017 meeting in Chicago. European biotech was in the spotlight during this year's edition of…
Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the…
Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one…
Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what…
While some might accuse the field of being over-hyped, immuno-oncology continues to attract attention and investment for its potential to cure cancer. What new therapies are European biotech cooking up? Since the…
Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno…
At Refresh in Paris, I had the opportunity to ask Eva-Lotta Allan,CBO of one of Europe's hottest companies, Immunocore, some pointed questions. Immunocore is famous as one of the biggest…